The global artificial lung market size was valued at USD 2.63 billion in 2025 and is projected to grow from USD 2.90 billion in 2026 to USD 6.50 billion by 2034, registering a CAGR of 10.61% during the forecast period (2026–2034). North America dominated the artificial lung marketwith a market share of 44.61% in 2025.
Artificial lungs are advanced medical devices designed to provide respiratory support by facilitating oxygen delivery and carbon dioxide removal from the blood when natural lung function is severely impaired. Artificial lungs support life-sustaining gas exchange and are increasingly integrated into extracorporeal life support therapies to improve patient outcomes and survival rates.
The artificial lung market demand is driven by the rising prevalence of respiratory disorders, growing incidence of acute respiratory distress syndrome (ARDS), and increasing need for advanced life-support technologies. Expanding critical care infrastructure, ongoing innovations in extracorporeal membrane oxygenation systems, and growing adoption of bridge-to-transplant therapies are supporting artificial lung market growth.
Download a Free Sample to Explore Detailed Market Insights
The development of wearable artificial lung platforms is emerging as a significant trend in the artificial lungs market, enabling patient mobility during prolonged respiratory support. Unlike conventional stationary extracorporeal systems, wearable designs focus on miniaturized pumps, low-resistance oxygenators, and portable power sources. According to the United Network for Organ Sharing (UNOS), over 1,000 lung transplants were performed in the United States during the first half of 2025, highlighting demand for bridge-to-transplant technologies.
Biohybrid artificial lungs incorporating endothelial cell-lined gas exchange membranes are becoming an important market trend. These systems aim to reduce thrombosis, inflammation, and coagulation complications commonly associated with conventional artificial lung devices. By mimicking the biological properties of natural blood vessels, endothelialized membranes are improving hemocompatibility and supporting longer-duration extracorporeal respiratory support, accelerating innovation in next-generation artificial lung development pathways globally.
The artificial lung market forecasts increasing investments driven by rising demand for advanced extracorporeal life support systems, next-generation oxygenation technologies, and portable respiratory support devices. Investors are showing growing interest in companies developing artificial lungs, ECMO platforms, and bioengineered respiratory support solutions. The increasing prevalence of respiratory failure and ongoing innovation in long-term lung replacement technologies are further strengthening funding activity across the market.
Key Investment and Funding Activities in Artificial Lung Market, 2025–2026
Breethe Inc.
February 2026
USD 3 Million
Received funding support to advance development of portable extracorporeal membrane oxygenation and artificial lung technologies.
Alung Technologies
November 2025
USD 10 Million
Funding directed toward advancing low-flow extracorporeal carbon dioxide removal and artificial lung platform development.
Lung Biotechnology PBC
October 2025
USD 12 Million
Investment utilized to accelerate bioartificial lung research, engineering activities, and respiratory support innovation programs.
Rising Demand for Bridge-to-Transplant Respiratory Support and Growing Adoption of Extracorporeal CO2 Removal for Respiratory Failure Drives Market
The increasing use of artificial lungs as bridge-to-transplant support systems is driving market growth by helping patients survive while awaiting donor lungs. According to the Organ Procurement and Transplantation Network (OPTN), more than 2,800 lung transplants were performed in the US during 2025. Artificial lung technologies provide extended respiratory support for critically ill patients, increasing their importance within advanced transplant care pathways, which, in turn, drives market growth.
The increasing utilization of extracorporeal carbon dioxide removal (ECCO₂R) therapies is a major market driver for artificial lung technologies. These systems selectively remove carbon dioxide while reducing the need for invasive mechanical ventilation in patients with severe hypercapnic respiratory failure. Growing clinical emphasis on lung-protective ventilation strategies and minimizing ventilator-associated complications is strengthening adoption of artificial lung platforms within intensive care and critical care environments worldwide.
Limited Hemocompatibility and Dependence on Specialized Extracorporeal Care Infrastructure Restrain Market
Artificial lung systems face challenges in maintaining long-term hemocompatibility because continuous blood contact with synthetic membranes can trigger clot formation, inflammation, and coagulation responses. These complications often necessitate anticoagulation therapy and increase clinical management complexity. According to the US Food and Drug Administration, thrombosis remains among the most frequently monitored risks associated with extracorporeal life-support technologies, limiting prolonged artificial lung utilization in critical care settings.
The artificial lung market is restrained by its dependence on highly specialized intensive care infrastructure, trained perfusionists, and multidisciplinary extracorporeal support teams. Artificial lung systems require continuous monitoring, advanced critical care resources, and complex patient management protocols. Limited availability of specialized extracorporeal support centers, particularly in developing healthcare systems, restricts accessibility and slows adoption of advanced artificial lung technologies across broader patient populations.
Development of Ambulatory Artificial Lung Systems and Expansion of Bioengineered Lung Replacement Technologies Offer Growth Opportunities for Artificial Lung Market Players
A key artificial lung market growth opportunity stems from the transition from intensive-care-based respiratory support to ambulatory artificial lung systems. Portable devices can potentially support patients outside traditional critical care settings while awaiting transplantation. According to the Organ Procurement and Transplantation Network, more than 1,000 candidates remained on the US lung transplant waiting list during 2025. This creates opportunities for mobility-focused long-term respiratory support technologies.
Advances in tissue engineering and regenerative medicine are creating opportunities for bioengineered artificial lung development. Researchers are increasingly exploring decellularized lung scaffolds, endothelialized membranes, and regenerative respiratory tissues to overcome donor organ shortages. According to the World Health Organization, chronic respiratory diseases affect hundreds of millions globally. The growing unmet need for long-term lung replacement solutions creates substantial opportunities for next-generation artificial lung technologies.
Maintaining Long-term Gas Exchange Efficiency and Balancing Anticoagulation Requirements Presents Challenges to Artificial Lung Market Growth
Maintaining stable gas exchange performance over extended support durations remains a major challenge in the artificial lung market. Protein deposition, fibrin accumulation, and membrane fouling can gradually reduce oxygen transfer and carbon dioxide removal efficiency. These performance declines may require device replacement or intervention, increasing treatment complexity and limiting the feasibility of long-term extracorporeal respiratory support applications.
Artificial lung systems require continuous blood-contacting circulation, making anticoagulation essential to prevent clot formation within extracorporeal circuits. However, prolonged anticoagulant use increases the risk of bleeding complications, particularly in critically ill patients. Achieving an optimal balance between thrombosis prevention and bleeding management remains a complex clinical challenge, affecting broader adoption and long-duration utilization of artificial lung technologies.
Based on product type, extracorporeal membrane oxygenation (ECMO) systems accounted for a share of 41.87% in 2025 due to their established use in acute cardiopulmonary failure management, compatibility with existing intensive care infrastructure, and ability to provide rapid full-body oxygenation support. Their integration with critical care transport programs and multidisciplinary ECMO teams further strengthens adoption across advanced tertiary healthcare settings.
The intracorporeal artificial lungs segment is expected to grow at a CAGR of around 11.36% during the forecast period, owing to increasing research into implantable respiratory support systems, growing emphasis on patient mobility during long-term therapy, and development of compact gas-exchange technologies designed to reduce dependence on external extracorporeal circuits and prolonged intensive care support requirements.
In 2025, bridge-to-transplantation accounted for a share of 40.71% in the artificial lung market, by active ingredient. This is due to increasing utilization of temporary respiratory support systems for maintaining transplant eligibility, preserving organ function during waiting periods, and stabilizing critically ill patients. Artificial lung technologies play an important role in managing severe respiratory failure while suitable donor organs remain unavailable.
The long-term support for chronic lung diseases segment is expected to grow at a CAGR of 11.68% during the forecast period, driven by rising interest in ambulatory respiratory support technologies, rising focus on reducing prolonged mechanical ventilation dependency, and ongoing development of biocompatible artificial lung systems designed for extended-duration respiratory assistance outside acute hospital environments.
By end user, tertiary care hospitals accounted for a share of 51.27% in 2025 due to availability of dedicated extracorporeal life support teams, advanced cardiothoracic surgery capabilities, and specialized critical care infrastructure. These institutions routinely manage complex respiratory failure cases requiring continuous monitoring, multidisciplinary expertise, and immediate access to advanced life-support technologies.
The transplant centers segment is expected to grow at a CAGR of 12.04% during the forecast period, driven by increasing integration of artificial lungs into transplant preparation pathways, growing utilization of organ-preservation support strategies, and expanding focus on maintaining patient stability before transplantation through specialized respiratory support and advanced peri-transplant care programs.
North America: Market Dominance Led by Presence of Highly Developed Extracorporeal Life Support Networks and Widespread Deployment of Advanced Cardiothoracic ICUs
The North America artificial lung market accounted for the largest regional share of 44.61% in 2025, driven by presence of highly developed extracorporeal life support networks, specialized perfusion workforce availability, and advanced transplant referral systems. As a region-specific example, the Extracorporeal Life Support Organization (ELSO) reports that North America hosts the largest concentration of ELSO-member centers globally, supporting broad utilization of advanced respiratory support technologies across critical care facilities.
The US artificial lung market was valued at USD 1.02 billion in 2025, driven by country's highly structured lung transplantation ecosystem and widespread deployment of advanced cardiothoracic intensive care units. Artificial lung systems are increasingly integrated into bridge-to-transplant and bridge-to-recovery pathways. The availability of dedicated extracorporeal support teams, centralized transplant coordination systems, and advanced respiratory failure management protocols continues to strengthen adoption across major healthcare institutions nationwide.
The artificial lung market in Canada was valued at USD 152.52 million in 2025, supported by increasing emphasis on equitable access to advanced respiratory care across geographically dispersed populations. Large transport distances between tertiary centers and remote communities have strengthened the need for highly coordinated extracorporeal support pathways. The country's integrated provincial healthcare networks and centralized critical care referral models support efficient deployment of advanced respiratory support technologies within specialized treatment facilities.
Asia Pacific: Fastest Growth Driven by Increasing Investments in Critical Care Infrastructure and High Prevalence of Chronic Pulmonary Disorders
The Asia Pacific artificial lung market is expected to grow at a CAGR of 12.59% during the forecast period, showcasing fastest regional growth. This growth is driven by increasing investments in critical care infrastructure, rising availability of specialized cardiothoracic services, and ongoing modernization of tertiary healthcare facilities. Growing healthcare expenditure and expanding access to advanced respiratory support technologies are strengthening adoption. The region is increasingly prioritizing high-acuity respiratory care capabilities to address complex cardiopulmonary conditions requiring specialized intervention.
The China artificial lung market was valued at USD 157.37 million in 2025, supported by rapid expansion of high-level intensive care infrastructure and increasing investments in advanced respiratory medicine capabilities. As a country-specific example, according to the National Health Commission of China, the country has significantly expanded intensive care bed capacity since recent healthcare modernization initiatives. This strengthening critical care infrastructure is creating favorable conditions for broader adoption of artificial lung and extracorporeal respiratory support technologies.
The India artificial lung market was valued at USD 83.60 million in 2025, driven by rapid expansion of advanced critical care services and increasing establishment of dedicated ECMO-capable tertiary hospitals. Growing investments in high-acuity respiratory care and cardiothoracic treatment infrastructure are supporting adoption of artificial lung technologies. As a market-specific example, according to the National Organ and Tissue Transplant Organization (NOTTO), lung transplantation activity has steadily increased in India in recent years, strengthening demand for bridge-to-transplant respiratory support systems and specialized extracorporeal life-support capabilities.
The Japanese artificial lung market was valued at USD 103.28 million in 2025, supported by increasing demand for advanced respiratory support associated with the country's aging population and high prevalence of chronic pulmonary disorders. The healthcare system's emphasis on precision critical care, specialized respiratory management, and technologically advanced treatment pathways supports utilization of artificial lung technologies in the country. According to Japan's Ministry of Internal Affairs and Communications, nearly 30% of the population was aged 65 years or older in 2025, increasing demand for advanced respiratory and critical care services. Strong integration of life-support systems within tertiary care settings further contributes to market expansion.
The artificial lungs market competitive landscape is moderately consolidated, comprising medical device manufacturers, extracorporeal life support specialists, perfusion technology providers, and emerging bioengineering innovators. Established participants compete through membrane technology expertise, oxygenation efficiency, critical care integration, and extensive clinical support capabilities. The artificial lungs market ecosystem is shaped by ongoing advancements in extracorporeal technologies, growing transplant support requirements, critical care infrastructure expansion, and increasing research activity surrounding next-generation biohybrid and regenerative lung replacement platforms.
Recent Industry Developments
October 2025: Medtronic launched its VitalFlow ECMO system in Europe, expanding its extracorporeal life-support portfolio for critical care and intra-hospital transport.
September 2025: Inspira Technologies expanded the clinical use of its INSPIRA ART100 system into lung transplant procedures at a top US hospital, strengthening its advanced respiratory support applications.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com